Prescription Drug Prices:
Analysis of Canada's Patented Medicine Prices Review Board
HRD-93-51: Published: Feb 17, 1993. Publicly Released: Feb 22, 1993.
Additional Materials:
- Full Report:
Contact:
Pursuant to a congressional request, GAO: (1) described the purpose and structure of Canada's Patented Medicine Prices Review Board as well as its guidelines and procedures, especially those used to determine if a drug price is excessive; and (2) summarized the evidence about the effects of the Board's actions on the prices of new drugs, on price increases for existing drugs, and on pharmaceutical research and development.
GAO found that: (1) the Board is the federal body responsible for restraining prescription drug prices in Canada; (2) the Board periodically publishes guidelines that it uses to determine whether a manufacturer's introductory price on a new drug or price increase on an older patented drug is excessive; (3) the Board has the power to order the removal of market exclusivity or a price reduction if it finds a price to be excessive; (4) Canadian experience shows that a drug price review board can restrain prescription drug prices; (5) statistical analyses suggest that Canadian prices of new patented drugs subject to Board review were, on average, one-third lower than had there been no Board; and (6) restraint of drug prices reduces the incentive for manufacturers to undertake innovative pharmaceutical research and development.
Jun 26, 2020
COVID-19:
Opportunities to Improve Federal Response and Recovery EffortsGAO-20-659T: Published: Jun 26, 2020. Publicly Released: Jun 26, 2020.
Jun 25, 2020
-
Covid-19:
Opportunities to Improve Federal Response and Recovery EffortsGAO-20-625: Published: Jun 25, 2020. Publicly Released: Jun 25, 2020.
Jun 18, 2020
-
Public Health Preparedness:
HHS Should Take Actions to Ensure It Has an Adequate Number of Effectively Trained Emergency RespondersGAO-20-525: Published: Jun 18, 2020. Publicly Released: Jun 18, 2020.
Jun 12, 2020
-
Domestic Violence:
Improved Data Needed to Identify the Prevalence of Brain Injuries among VictimsGAO-20-534: Published: Jun 12, 2020. Publicly Released: Jun 12, 2020.
Jun 5, 2020
-
Electronic Health Records:
Ongoing Stakeholder Involvement Needed in the Department of Veterans Affairs' Modernization EffortGAO-20-473: Published: Jun 5, 2020. Publicly Released: Jun 5, 2020.
Jun 4, 2020
-
Infectious Disease Modeling:
Opportunities to Improve Coordination and Ensure ReproducibilityGAO-20-372: Published: May 13, 2020. Publicly Released: Jun 4, 2020.
Jun 2, 2020
-
Drug Safety:
COVID-19 Complicates Already Challenged FDA Foreign Inspection ProgramGAO-20-626T: Published: Jun 2, 2020. Publicly Released: Jun 2, 2020.
Jun 1, 2020
-
Medicaid:
State Views on Program Administration ChallengesGAO-20-407: Published: Apr 30, 2020. Publicly Released: Jun 1, 2020.
May 21, 2020
-
Medicare:
CMS Should Provide Beneficiaries More Information about Substance Use Disorder CoverageGAO-20-408: Published: May 21, 2020. Publicly Released: May 21, 2020.
May 20, 2020
-
Infection Control Deficiencies Were Widespread and Persistent in Nursing Homes Prior to COVID-19 PandemicGAO-20-576R: Published: May 20, 2020. Publicly Released: May 20, 2020.
Looking for more? Browse all our products here
Explore our Key Issues on Health Care
- Air Quality
- Children's Health and Safety
- Elder Abuse
- Federal Efforts to Prevent Drug Misuse
- Health Care Quality
- Health Information Technology
- Improving Federal Programs that Serve Tribes and Their Members - High Risk Issue
- Managing Risks and Improving VA Health Care
- Medicaid - High Risk Issue
- Medical Product Oversight - High Risk Issue
- Medicare - High Risk Issue
- Prescription Drug Spending
- Reducing Government-wide Improper Payments
- Supports and Services for Transitioning Veterans
- Toxic Chemicals - High Risk Issue
- VA and DOD Health Care Management
- VA and DOD Patient Care
Explore our other Key Issues here
